<DOC>
	<DOCNO>NCT00875446</DOCNO>
	<brief_summary>The drug test study GSK1223249 . It develop GlaxoSmithKline treat symptom patient Amyotrophic Lateral Sclerosis ( ALS ) . The drug work inhibit protein prevents nerve growth . This first time drug give man . The trial expect involve approximately 76 patient . The study objective investigate tolerability , safety way body handle GSK1223249 range single dose repeat dose escalation patient ALS .</brief_summary>
	<brief_title>First Time Human Study GSK1223249 Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This first-time-in-human ( FTIH ) phase I/IIa study GSK1223249 , humanise monoclonal antibody Nogo-A , neurite outgrowth inhibitor hypothesise involved pathophysiology amyotrophic lateral sclerosis ( ALS ) neurodegenerative disorder . This study randomize , placebo-controlled , double-blind , sequential dose escalation , 2-part fusion protocol . Approximately 76 patient ALS enrol . In Part 1 , single escalate intravenous ( i.v . ) dose GSK1223249 plan evaluate 5 sequential patient cohort ( 2 placebo 6 active cohort ) determine single dose safety pharmacokinetics ( PK ) . Part 2 also sequential dose escalate design , patient plan 3 cohort ( 3 placebo , 9 active cohort ) receive 2 repeat i.v . dose approximately 4 week apart , safety PK also evaluate . In two cohort Part 1 cohort Part 2 , blood sample skeletal muscle biopsy take patient end treatment demonstrate whether GSK1223249 bind target produce measurable pharmacodynamic effect . Patients part receive first dose hospital-based unit monitor least 24 hour post-dose discharge follow out-patient basis . In cohort part 1 , first four subject dose stagger manner one receive dose 24 hour . Dosing first four subject first cohort part 2 also stagger similar manner .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients diagnosis familial sporadic ALS , define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord revise World Federation Neurology El Escorial criterion [ Rix Brooks 2000 ] . Onset muscle weakness within 60 month study entry . Patients low Slow Inspiratory Vital Capacity ( SVC ) predict age sex include study discretion investigator long NOT respiratory insufficient . If medication ( include riluzole ) , must stable within previous one month . ( See also 'Concomitant Medications ' Section 8 ) . Age 18 80 year inclusive . Male Female nonchildbearing potential ( NCBP ) define follow : Premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml oestradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 7.1.1 , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Male subject must agree use one contraception method list Section 7.1.2 . This criterion must follow time first dose study medication last followup visit . QTcB &lt; 500 msec uncorrected QT &lt; 600msec ( machine manual overread ) . If subject bundle branch block criterion QTcB &lt; 530 msec . A Body Mass Index discretion investigator acceptable inclusion study . Capable give write informed consent , include compliance requirement restriction list consent form . Patients neuromuscular disorder ( addition ALS diagnosis ) , unless investigator determines additional disorder affect safety measure study . Patients evidence dementia psychiatric illness , investigator 's opinion , likely prevent full understanding and/or compliance study requirement procedure . Patients abnormality detect screen evaluation , investigator 's medical judgement , sufficiently significant exclude participation study . Patients participate clinical trial involve receipt biopharmaceutical product within 6 month prior first dose day . Exposure four new investigational product within 12 month prior first dose day . The subject positive drug abuse test screen pre dose visit . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates benzodiazepine . Subjects drug prescription medical reason may consider investigator inclusion fulfil entry criterion . The subject positive alcohol test predose visit . History regular excessive alcohol consumption within 6 month study define : For European site : average weekly intake &gt; 28 unit male &gt; 21 unit female . One unit equivalent 8g alcohol : halfpint ( ~240mL ) beer , 1 glass ( 125mL ) wine 1 ( 25mL ) measure spirit . For North American site : average weekly intake &gt; 21 drink male &gt; 14 drink woman . One drink equivalent 12 g alcohol : 12 ounce ( 360mL ) beer , 5 ounce ( 150mL ) wine 1.5 ounce ( 45mL ) 80 proof distil spirit . History sensitivity GSK1223249 , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Females childbearing potential , pregnant female determine positive serum urine beta hCG test screen prior dosing , lactate female . Patients receive type vaccination last 3 week study drug administration . Unwillingness inability follow procedure outline protocol Subjects undergo muscle biopsy ( cohort 3optional 5 , 6 , 7 8 eligible inclusion , follow criterion apply : Patients waste deltoid ( MRC score â‰¤ 2 ) patient normal deltoid ( MRC score 5 ) . Patients achieve normal coagulation perioperative period may otherwise high risk bleeding complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>